Share on StockTwits

Galectin Therapeutics (NASDAQ:GALT) Director Arthur Greenberg bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was purchased at an average cost of $4.56 per share, for a total transaction of $4,560.00. Following the completion of the acquisition, the director now directly owns 96,667 shares of the company’s stock, valued at approximately $440,802. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Galectin Therapeutics (NASDAQ:GALT) opened at 5.08 on Thursday. Galectin Therapeutics has a 52-week low of $4.28 and a 52-week high of $19.11. The stock’s 50-day moving average is $9.41 and its 200-day moving average is $12.58. The company’s market cap is $112.0 million.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-1.03 earnings per share for the current fiscal year.

GALT has been the subject of a number of recent research reports. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.

Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.

Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.